CO-CSG
11.6.2019 14:02:05 CEST | Business Wire | Press release
As new digital services are deployed to help communications service providers (CSPs) drive innovation, 5G core networks are becoming a necessity to enable true service differentiation. This need is quickly becoming realized, with two-thirds of organizations1 planning to deploy 5G by the end of next year. Not only will CSPs be expected to deliver a fully functional 5G network to meet end-user demand, but success will lie in the ability to provide innovative digital services and to fully monetize their 5G infrastructure investment.
Today, CSG announced the availability of its new 5G Dynamic Charging Function, designed to help CSPs optimize their strategy to not only deliver the value of 5G networks to customers, but also to optimize for sustainable growth in the digital economy. This new capability fulfils the roles of both the 5G Charging Function (CHF) and the Charging Gateway Function (CGF), providing offline and online mediation functionality in a single platform, while managing the complexity of all interfaces between the network and the BSS functions.
“The revenue potential resulting from the deployment of 5G networks should not be underestimated,” said Chad Dunavant, global head of product management, CSG. “But the next generation of business, from 5G to the Internet of Things, requires fundamentally new businesses models. The CSG 5G Dynamic Charging Function gives CSPs the foundation they need to capitalize and monetize on complete industry transformation.”
The CSG 5G Dynamic Charging solution enables operators to:
- Drive service differentiation : Facilitate the monetization of network slicing, enabling charging of tenants and differentiated services by charging in-slice and across slices.
- Minimize risk and disruption to existing systems : Provides a cost effective and efficient way for service providers to seize the 5G opportunity.
- Elastically scale : Automatically scale up to process large charging volumes and down when traffic subsides to optimize infrastructure costs.
- Deliver unparalleled capacity : Process millions of transactions a second with low cost infrastructure to deploy.
- Automate operations : With intelligent tools for diagnostics and troubleshooting.
- Support critical services : Single-digit latencies for real-time online charging transactions.
- Be vendor independent : Support network functions and OSS/BSS systems from any vendor. Eliminates network equipment provider siloes.
- Preserve existing investments : Seamlessly manage the integration of service-based interfaces to existing online charging system interfaces for faster time to market.
With hundreds of global installations, CSG has one of the most trusted mediation and transaction management solutions in the world. CSG supports mediation across any domain, across all mediation functions, for all deployment approaches. The solution captures and processes customer usage events of all kinds from any service delivery network for industry leaders in digital communications and media, financial services, logistics and government.
For more information on how to effectively monetize 5G, download the latest CSG whitepaper here .
About CSG
CSG (NASDAQ: CSGS) is a provider of software and services that help companies around the world monetize and digitally enable the customer experience. For more than 35 years, CSG has simplified the complexity of business, providing revenue management and digital monetization, payments, and customer engagement solutions to help our customers tackle any business challenge and thrive in an ever-changing marketplace.
Operating across more than 120 countries worldwide, CSG manages billions of critical customer interactions annually. CSG is the trusted partner driving digital innovation for hundreds of leading global brands, including Arrow Electronics, AT&T, Charter Communications, Comcast, DISH, Eastlink, Formula One, iflix, MTN and Telstra.
To learn more, visit our website at csgi.com and connect with us on LinkedIn , Twitter and Facebook .
1 Gartner 5G Adoption Survey, December 2018
View source version on businesswire.com: https://www.businesswire.com/news/home/20190611005208/en/
Contact:
Brad Jones Public Relations CSG +1 (303) 200-3001 brad.jones@csgi.com Liz Bauer Investor Relations CSG +1 (303) 804-4065 liz.bauer@csgi.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom